Bouvel Investment Partners LLC Buys 67 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Bouvel Investment Partners LLC raised its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,950 shares of the medical equipment provider’s stock after buying an additional 67 shares during the quarter. Intuitive Surgical comprises about 2.5% of Bouvel Investment Partners LLC’s portfolio, making the stock its 8th largest position. Bouvel Investment Partners LLC’s holdings in Intuitive Surgical were worth $6,853,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in ISRG. Creekmur Asset Management LLC boosted its position in Intuitive Surgical by 200.0% in the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 42 shares in the last quarter. Ridgewood Investments LLC acquired a new stake in Intuitive Surgical during the 2nd quarter valued at approximately $26,000. Delos Wealth Advisors LLC raised its stake in Intuitive Surgical by 380.0% during the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 57 shares during the last quarter. Godsey & Gibb Inc. raised its position in shares of Intuitive Surgical by 140.0% in the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 35 shares in the last quarter. Finally, LRI Investments LLC acquired a new position in Intuitive Surgical in the first quarter valued at approximately $30,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ISRG. Truist Financial upped their price objective on shares of Intuitive Surgical from $520.00 to $570.00 and gave the company a “buy” rating in a report on Monday, October 14th. Oppenheimer reaffirmed a “market perform” rating on shares of Intuitive Surgical in a report on Friday, October 18th. Barclays upped their target price on Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a report on Thursday, July 18th. Mizuho raised their price objective on shares of Intuitive Surgical from $440.00 to $500.00 in a report on Thursday, October 17th. Finally, Stifel Nicolaus boosted their target price on Intuitive Surgical from $475.00 to $525.00 and gave the company a “buy” rating in a research note on Friday, October 18th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat, Intuitive Surgical currently has an average rating of “Moderate Buy” and an average price target of $513.74.

Intuitive Surgical Price Performance

Shares of NASDAQ:ISRG opened at $536.69 on Thursday. Intuitive Surgical, Inc. has a 1 year low of $287.98 and a 1 year high of $542.59. The company has a market cap of $191.16 billion, a PE ratio of 86.28, a P/E/G ratio of 5.28 and a beta of 1.39. The stock’s 50-day moving average is $495.85 and its 200 day moving average is $455.08.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.24 by $0.32. The company had revenue of $2.04 billion for the quarter, compared to analysts’ expectations of $2.01 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. Analysts expect that Intuitive Surgical, Inc. will post 5.45 EPS for the current fiscal year.

Insider Activity

In related news, SVP Henry L. Charlton sold 40,243 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the transaction, the senior vice president now owns 3,001 shares of the company’s stock, valued at $1,461,006.84. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, SVP Henry L. Charlton sold 40,243 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total value of $19,591,902.12. Following the transaction, the senior vice president now directly owns 3,001 shares of the company’s stock, valued at approximately $1,461,006.84. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Jamie Samath sold 22,903 shares of Intuitive Surgical stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $525.00, for a total value of $12,024,075.00. Following the completion of the sale, the insider now owns 8,757 shares of the company’s stock, valued at $4,597,425. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 91,178 shares of company stock worth $45,897,071. Corporate insiders own 0.90% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.